Quality Assurance in Rectal Cancer Management

  • Anne J. Breugom
  • Petra G. Boelens
  • Cornelis J. H. van de Velde
Chapter

Abstract

Rectal cancer management has evolved over the past decades. Major improvements in locoregional recurrence rates and survival were made by the introduction of total mesorectal excision (TME). The use of preoperative (chemo)radiation and the possibility of more accurate staging with MRI scanning resulted in further improvements in rectal cancer outcomes.

To further optimise and improve the quality of rectal cancer care, quality assurance in rectal cancer treatment is of great importance. Auditing is an effective instrument to monitor the quality of care and to improve outcome. Other tools to improve the quality of rectal cancer care are for example guideline formation, multidisciplinary team management, and care pathways.

Keywords

Quality assurance Audit Multidisciplinarity Guidelines Quality indicators Cancer registry 

References

  1. 1.
    Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.PubMedCrossRefGoogle Scholar
  2. 2.
    Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery–the clue to pelvic recurrence? Br J Surg. 1982;69(10):613–6.PubMedCrossRefGoogle Scholar
  3. 3.
    MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet. 1993;341(8843):457–60.PubMedCrossRefGoogle Scholar
  4. 4.
    Quirke P, Steele R, Monson J, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet. 2009;373(9666):821–8.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    MERCURY Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ. 2006;333(7572):779.PubMedCentralCrossRefGoogle Scholar
  6. 6.
    MERCURY Study Group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology. 2007;243(1):132–9.CrossRefGoogle Scholar
  7. 7.
    Taylor FG, Quirke P, Heald RJ, et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg. 2011;253(4):711–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Taylor FG, Quirke P, Heald RJ, et al. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol. 2014;32(1):34–43.PubMedCrossRefGoogle Scholar
  9. 9.
    Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638–46.PubMedCrossRefGoogle Scholar
  10. 10.
    De Caluwe L, Van NY, Ceelen WP. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev. 2013;(2):CD006041.Google Scholar
  11. 11.
    Breugom AJ, Boelens PG, van den Broek CB, et al. Quality assurance in the treatment of colorectal cancer: the EURECCA initiative. Ann Oncol. 2014;25(8):1485–92.PubMedCrossRefGoogle Scholar
  12. 12.
    Brand RA. Ernest Amory Codman, MD, 1869–1940. Clin Orthop Relat Res. 2009;467(11):2763–5.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Wibe A, Moller B, Norstein J, et al. A national strategic change in treatment policy for rectal cancer–implementation of total mesorectal excision as routine treatment in Norway. A national audit. Dis Colon Rectum. 2002;45(7):857–66.PubMedCrossRefGoogle Scholar
  14. 14.
    Wibe A, Eriksen MT, Syse A, Myrvold HE, Soreide O. Total mesorectal excision for rectal cancer–what can be achieved by a national audit? Colorectal Dis. 2003;5(5):471–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Wibe A, Carlsen E, Dahl O, et al. Nationwide quality assurance of rectal cancer treatment. Colorectal Dis. 2006;8(3):224–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Ortiz H, Wibe A, Ciga MA, Lujan J, Codina A, Biondo S. Impact of a multidisciplinary team training programme on rectal cancer outcomes in Spain. Colorectal Dis. 2013;15(5):544–51.PubMedCrossRefGoogle Scholar
  17. 17.
    EUROCARE. http://www.eurocare.it. Last accessed 30 Mar 2014.
  18. 18.
    Berrino F. The EUROCARE Study: strengths, limitations and perspectives of population-based, comparative survival studies. Ann Oncol. 2003;14 Suppl 5:v9–13.PubMedCrossRefGoogle Scholar
  19. 19.
    Verdecchia A, Francisci S, Brenner H, et al. Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007;8(9):784–96.PubMedCrossRefGoogle Scholar
  20. 20.
    De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE–5-a population-based study. Lancet Oncol. 2014;15(1):23–34.PubMedCrossRefGoogle Scholar
  21. 21.
    Quirke P, West NP, Nagtegaal ID. EURECCA consensus conference highlights about colorectal cancer clinical management: the pathologists expert review. Virchows Arch. 2014;464(2):129–34.PubMedCrossRefGoogle Scholar
  22. 22.
    Pahlman L, Bohe M, Cedermark B, et al. The Swedish rectal cancer registry. Br J Surg. 2007;94(10):1285–92.PubMedCrossRefGoogle Scholar
  23. 23.
    Birgisson H, Talback M, Gunnarsson U, Pahlman L, Glimelius B. Improved survival in cancer of the colon and rectum in Sweden. Eur J Surg Oncol. 2005;31(8):845–53.PubMedCrossRefGoogle Scholar
  24. 24.
    Gooiker GA, Kolfschoten NE, Bastiaannet E, et al. Evaluating the validity of quality indicators for colorectal cancer care. J Surg Oncol. 2013;108(7):465–71.PubMedCrossRefGoogle Scholar
  25. 25.
    van de Velde CJ, Boelens PG, Borras JM, et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. Eur J Cancer. 2014;50(1):1.PubMedGoogle Scholar
  26. 26.
    Tudyka V, Blomqvist L, Beets-Tan RG, et al. EURECCA consensus conference highlights about colon & rectal cancer multidisciplinary management: the radiology experts review. Eur J Surg Oncol. 2013;40(4):469–75.PubMedCrossRefGoogle Scholar
  27. 27.
    Valentini V, Glimelius B, Haustermans K, et al. EURECCA consensus conference highlights about rectal cancer clinical management: the radiation oncologist’s expert review. Radiother Oncol. 2013;110(1):195–8.PubMedCrossRefGoogle Scholar
  28. 28.
    van de Velde CJ, Boelens PG, Tanis PJ, et al. Experts reviews of the multidisciplinary consensus conference colon and rectal cancer 2012: science, opinions and experiences from the experts of surgery. Eur J Surg Oncol. 2013;40(4):454–68.PubMedCrossRefGoogle Scholar
  29. 29.
    Wille-Jorgensen P, Sparre P, Glenthoj A, et al. Result of the implementation of multidisciplinary teams in rectal cancer. Colorectal Dis. 2013;15(4):410–3.PubMedCrossRefGoogle Scholar
  30. 30.
    Swellengrebel HA, Peters EG, Cats A, et al. Multidisciplinary discussion and management of rectal cancer: a population-based study. World J Surg. 2011;35(9):2125–33.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Palmer G, Martling A, Cedermark B, Holm T. Preoperative tumour staging with multidisciplinary team assessment improves the outcome in locally advanced primary rectal cancer. Colorectal Dis. 2011;13(12):1361–9.PubMedCrossRefGoogle Scholar
  32. 32.
    MacDermid E, Hooton G, MacDonald M, et al. Improving patient survival with the colorectal cancer multi-disciplinary team. Colorectal Dis. 2009;11(3):291–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Kehlet H. Multimodal approach to control postoperative pathophysiology and rehabilitation. Br J Anaesth. 1997;78(5):606–17.PubMedCrossRefGoogle Scholar
  34. 34.
    Kehlet H, Slim K. The future of fast-track surgery. Br J Surg. 2012;99(8):1025–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346(15):1128–37.PubMedCrossRefGoogle Scholar
  36. 36.
    Dudley RA, Johansen KL, Brand R, Rennie DJ, Milstein A. Selective referral to high-volume hospitals: estimating potentially avoidable deaths. JAMA. 2000;283(9):1159–66.PubMedCrossRefGoogle Scholar
  37. 37.
    Archampong D, Borowski D, Wille-Jorgensen P, Iversen LH. Workload and surgeon’s specialty for outcome after colorectal cancer surgery. Cochrane Database Syst Rev. 2012;(3):CD005391.Google Scholar
  38. 38.
    Bergs J, Hellings J, Cleemput I, et al. Systematic review and meta-analysis of the effect of the World Health Organization surgical safety checklist on postoperative complications. Br J Surg. 2014;101(3):150–8.PubMedCrossRefGoogle Scholar
  39. 39.
    de Vries EN, Prins HA, Crolla RM, et al. Effect of a comprehensive surgical safety system on patient outcomes. N Engl J Med. 2010;363(20):1928–37.PubMedCrossRefGoogle Scholar
  40. 40.
    de Vries EN, Eikens-Jansen MP, Hamersma AM, Smorenburg SM, Gouma DJ, Boermeester MA. Prevention of surgical malpractice claims by use of a surgical safety checklist. Ann Surg. 2011;253(3):624–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Snijders HS, Kunneman M, Bonsing BA, et al. Preoperative risk information and patient involvement in surgical treatment for rectal and sigmoid cancer. Colorectal Dis. 2014;16(2):O43–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Stalmeier PF, van Tol-Geerdink JJ, van Lin EN, et al. Doctors’ and patients’ preferences for participation and treatment in curative prostate cancer radiotherapy. J Clin Oncol. 2007;25(21):3096–100.PubMedCrossRefGoogle Scholar
  43. 43.
    Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29(35):4633–40.PubMedCrossRefGoogle Scholar
  44. 44.
    Habr-Gama A, Sabbaga J, Gama-Rodrigues J, et al. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management? Dis Colon Rectum. 2013;56(10):1109–17.PubMedCrossRefGoogle Scholar
  45. 45.
    Wynn GR, Bhasin N, Macklin CP, George ML. Complete clinical response to neoadjuvant chemoradiotherapy in patients with rectal cancer: opinions of British and Irish specialists. Colorectal Dis. 2010;12(4):327–33.PubMedCrossRefGoogle Scholar
  46. 46.
    Stacey D, Bennett CL, Barry MJ, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2011;(10):CD001431.Google Scholar

Copyright information

© Springer-Verlag London 2015

Authors and Affiliations

  • Anne J. Breugom
    • 1
  • Petra G. Boelens
    • 1
  • Cornelis J. H. van de Velde
    • 1
  1. 1.Department of SurgeryLeiden University Medical CenterLeidenThe Netherlands

Personalised recommendations